OPRX

FY2025 is OptimizeRx's inflection year. After a string of GAAP losses (FY2024 net income -$20.1M), the company swung to $5.13M net income (+125.5%), operating income jumped to $11.7M (+185.3%) on $109M revenue (+18.8%), and operating cash flow exploded to $18.7M (+282.8%). At $5.43 the entire equity is valued at ~$102M — roughly 5.4x operating cash flow and 0.9x sales — which is a strikingly low multiple for a 67.3% gross-margin software/data platform that just turned cash-generative. The MD&A explains the margin path: higher-margin DAAP/Micro-Neighborhood Targeting and a deliberate push to transition customers to predictable subscription data services, which management expects to lift margin, visibility and revenue predictability over time.

The balance sheet de-risks the call. Cash rose 74.6% to $23.4M against ~$25.6M total debt (LT $21.4M, down 30.5%, plus $4.25M current), so the company is essentially net-debt-neutral, with liabilities/equity of just 0.38x and equity of $128M. Capex is negligible ($58K), so OCF is nearly free cash flow. Crucially, on March 5, 2026 the Board authorized a new $10M buyback (effective March 12, 2026) — about 10% of the entire market cap — a credible signal and a real source of demand for a thinly-held name (only ~243 holders of record, 18.8M shares).